

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

Dear registered shareholder(s),

9 April 2025

Reminder letter regarding the arrangement of Electronic Dissemination of Corporate Communications (Note 1)

With reference to the notification letter dated 1 March 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Genscript Biotech Corporation (the "Company") is writing to remind you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"). Corporate Communications mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at https://www.genscript.com/announcements-circulars.html and the HKExnews website at www.hkexnews.hk in place of printed copies. The Company will not send a notice of publication of the Corporate Communications on the website of the Company and HKExnews to you. You are encouraged to proactively monitor the availability of all future Corporate Communications on the websites and access the Corporate Communications via the websites above by yourselves.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications (Note 2), the Company recommends you to provide your email address by scanning your personalized QR code printed on the reply form on the reverse side (the "**Reply Form**") if you have not yet provided your email address to the Company. Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "**Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications $(Note^2)$ in printed form in future.

If you wish to receive the future Corporate Communications in printed form, please complete and return the Reply Form to the Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, or send an email to genscript.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction unless being superseded by a subsequent instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Note 1: This letter is addressed to registered shareholders of the Company who have not yet provided an email address for the timely receipt of actionable corporate communications. If you are a new registered shareholder, please read the arrangement for the electronic dissemination of corporate communications and provide your email address as recommended.

Note 2: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

以電子方式發布公司通訊安排之提示信函 (Mic 1)

根據日期為二零二四年三月一日有關「以電子方式發布公司通訊之安排」之通知信函所述,金斯瑞生物科技股份有限公司(「**本公司**」)謹此通知 閣下,謹此提醒 閣下,本公司已採用以電子方式發佈公司通訊(「**公司通訊**」)之安排。公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及(如適用)其中期報告摘要; (c)會議通知; (d)上市文件; (e)通函和 (f)代表委任表格。

請注意,所有未來公司通訊的英文版和中文版將在本公司網站 https://www.genscript.com.cn/announcements-circulars.html 和披露易網站 www.hkexnews.hk 上提供,以代替印刷本。本公司不會向 閣下發出公司通訊登載在本公司網站和披露易網站的登載通知。本公司鼓勵 閣下主動留意網站上所有日後的公司通訊的登載情況,並通過以上網站自行瀏覽公司通訊。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊^(網E2),如果 閣下尚未向本公司提供電子郵件地址,本公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。 或者, 閣下也可以簽署回條並交回本公司的香港股份過戶登記處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果本公司沒有收到 閣下的有效電子郵件地址,直至股份過戶處收到 閣下有效的電子郵件地址前,本公司未來將以印刷本形式發送可供採取行動的公司通訊 $^{(Me2)}$ 。

若 閣下希望收取日後公司通訊之印刷版,請填妥回條並交回股份過戶處香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓,或發送電子郵件至 genscript.ecom@computershare.com.hk ,並註明 閣下的姓名、地址以及收取公司通訊之印刷版的要求。 請注意,收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效(除非被後續接收之指示所替代),此後將過期。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午 9 時正至下午 6 時正(香港時間)其間致電股份過戶處(852)2862 8688 查詢。

承董事會命 Genscript Biotech Corporation 孟建革 *主席及執行董事* 謹啟

二零二五年四月九日

REPLY FORM 回條					
	Computershare Hong Kong Investor Services Limited (The "Share Registrar") 17M Floor, Hopewell Centre 183 Queen's Road East, Wan Chai, Hong Kong use choose ONLY ONE of the options below) 性以下選項中只選擇其中一項	致:	香港中央證券登記有限公司 (「股份過戶處」) 香港灣仔皇后大道東 183 號 合和中心 17M 樓		
	Provide email address for receipt of future Actionable Corporate Communications (Note 3) of the Company via electronic dissemination by scanning personalized QR code 選項1: 掃瞄 專屬二維碼提供電子郵件地址,以接收本公司通過電子方式 發佈的可供採取行動的未來公司通訊 (Math 3) Returning this Reply Form is NOT required if Option 1 is chosen. 如選擇了選項 1,無須交回本回條。				
Option 2: I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications (Notes 3) of the following listed company (the "Company") via electronic dissemination 選項 2: 本人/吾等現以書面提供本人/吾等的電子郵件地址・以確保收到以下上市公司(「本公司」)通過電子方式發佈的可供採取行動的未來公司通訊 (開註 3) Name of Securities holder(s) 證券持有人姓名: Name of the listed company 上市公司名稱: Genscript Biotech Corporation 金斯瑞生物科技股份有限公司					
En	mail address 電郵地址: (Notes 3 / 附註3)	13113			
	Detion 3: I/we hereby request for receipt of Corporate Communications * 達項 3: 本人/吾等現要求收取公司通訊*印刷版 (如適用・請在以下方付 receive future Corporate Communications* in printed copy and noted that this	格內劃上「✔」號 instruction is valid o)		

Notes 附註:

簽名: (附註 1&2)

Signature(s): (Notes 1&2)

- Notes 附近:

 1. Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.

 清海楚項安 阁下之所有資料。如圖聽名股東。則本回條須由所有聯名股東聯合簽署。方為有效。

 2. Any Reply Form with no signature or otherwise incorrectly completed will be void.

 任何回條若未有養審理核互换作方面傳承不正確,則本回條第會代發。

 3. If the Company does not receive a functional email address in your reply, the Company will send the Actionable Corporate Communications in printed form in future. Actionable Corporate Communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

 如公司受持权数 阁下的教授章于影件故址。本公司新以印刷本形式發送可供採取行動的未来公司通訊。可保服有動於公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利
 或作出選擇的公司通訊。可以可以可通訊。

Contact number:

聯絡電話號碼:

- 或作出資權的公司通訊。

 4. If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.

 如 關下通過二維傷、電影、回條及/或其他方式提供多於一個的電子影件地址、只有 關下最後提供的電子影件地址將會被用於登記。

 5. If you mark "" in the box in Option 3, no email address will be registered and only Corporate Communications" in printed form will be received.
 如 關下任題項 3方格內劃上 (*) 經,將不會海便子影件地址經濟記,只有公司通訊的印刷股 會被收取。

 6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.

 3. 是存是,在本回除上的任何影外活不,公司带不予處理。
 "Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form and Actionable Corporate Communication refers to any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

 [解于另有技印 公司通讯/指公司记录日期记录并有人的權利或作出選擇的公司通訊者任何涉及要求發行人的證券持有人指示其契如何行使其有關證券持有人的權利或作出選擇的公司通訊者任何涉及要求發行人的證券持有人提供自己。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料暨明

- "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
 本聲明中所指的「個人資料」與香港法例第 486 章 《個人資料(私隱)條例》(「《私隱條例》」)中「個人資料」的涵義相同。
 Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.

 圖下於本回條所提供的個人資料新用於(包括但不限於)有關公司以電子方式發布公司通訊及就 閣下持有的公司證券有關的其他事宜上與 閣下聯絡。閣下是自願向本公司提供個人資料。若閣下未能提供足夠資料。本公司可能無法處理 閣下在本回條上所述的指示及/或要求。 (ii)
- (iii)
- 本公司可能無法處理 閣下在本回像上所述的指示及/或要求。

 Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.

 公司可然任何所說明的用達或在法例規定的情况下,將 閣下的個人資料授權或轉移給公司的附屬公司、股份過戶處、及/或其他公司或團體、並將在適當期間保留該等個人資料作核實及紀錄用途。
 公司可然任何所說明的用達或在法例規定的情况下,將 閣下的個人資料授權或轉移給公司的附屬公司、股份過戶處、及/或其他公司或團體、並將在適當期間保留該等個人資料作核實及紀錄用途。
 为 Wou have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer(Recomputers) and the PDPO and PDPO and

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼: 37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

Date:

日期:

閣下寄回此回條時・請將郵寄標籤剪貼於信封上 如在本港投寄・ 閣下無需支付郵費或貼上郵票。